Replies to post #162822 on Biotech Values

[genisi]

PLX

The recombinant AAT sounds interesting too.

Note that PLX is going for inhaled formulation and they will know the results from KMDA's phase II/III of inhaled AAT in the same indication by early 2014. Interesting also since Kamada has an orphan drug designation in both EU and US.